A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

Trial Profile

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Aducanumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
  • Acronyms EMERGE
  • Sponsors Biogen
  • Most Recent Events

    • 19 Jan 2017 Planned End Date changed from 1 Feb 2022 to 1 Apr 2022.
    • 21 Apr 2016 Study design presented at the 68th Annual Meeting of the American Academy of Neurology
    • 08 Sep 2015 According to a Neurimmune media release, the first patient has been enrolled in the phase III program which includes this and another study (ENGAGE, CTP 700255220).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top